Retatrutide (LY3437943) is a novel triple agonist simultaneously targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, representing the next generation of metabolic therapeutics research. This unimolecular triple agonist demonstrates unprecedented efficacy in weight reduction and metabolic improvement by synergistically activating three complementary incretin pathways. Retatrutide enables investigation into comprehensive metabolic regulation through appetite suppression, enhanced energy expenditure, and improved insulin sensitivity.